Related Experiment Video
Updated: Oct 29, 2025
07:16
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
3.8K
Corticosteroid use in COVID-19 pneumonia.
Özlem Erçen Diken1, Fatma Yıldırım2, Pınar Yıldız Gülhan3
1Clinic of Chest Diseases, SBÜ Adana City Training and Research Hospital, Adana, Turkey.
Tuberkuloz Ve Toraks
|July 14, 2021
Summary
Short-term, low-dose corticosteroid treatment may improve outcomes for COVID-19 pneumonia patients without ARDS or septic shock. This therapy showed benefits in both acute and recovery phases, suggesting its potential role in managing COVID-19.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19) presents a significant fatality rate with undefined specific treatments.
- Corticosteroids are recommended for select COVID-19 patients, but consensus on patient subgroups, dosage, and duration is lacking.
- This study investigates corticosteroid therapy's impact on COVID-19 pneumonia management in acute (non-ARDS/septic shock) and recovery phases.
Purpose of the Study:
- To evaluate the efficacy of corticosteroid treatment in COVID-19 pneumonia patients.
- To assess the contribution of corticosteroids in both the acute and recovery phases of the illness.
- To determine the impact on clinical, radiological, and laboratory outcomes.
Main Methods:
- A cohort of 47 COVID-19 pneumonia patients was analyzed.
- Patients were divided into two groups: those receiving corticosteroids during the activation phase (non-ARDS/septic shock) and those during the recovery phase.
- Outcomes including clinical, radiological, and laboratory markers (D-dimer, ferritin, CRP, lymphocyte count, saturation) were assessed.
Main Results:
- Corticosteroid therapy led to reduced D-dimer, ferritin, fibrinogen, and CRP levels, and increased lymphocyte counts and saturation.
- Complete symptomatic improvement was observed in 6.9% of the activation group and 17.6% of the recovery group.
- Complete radiological improvement was seen in 11.5% of the activation group and 35.3% of the recovery group.
Conclusions:
- Short-term, low-dose corticosteroid therapy demonstrates potential benefits for COVID-19 pneumonia patients.
- The treatment appears effective in both the acute phase (without ARDS/septic shock) and the recovery phase.
- Further randomized controlled trials are warranted to confirm the efficacy of corticosteroid treatment in COVID-19 management.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
498
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
498
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
741
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
741
01:28Pneumonia IV: Management
528
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
528
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
252
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
252
01:22Chronic Obstructive Pulmonary Disease
1.7K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.7K